SCHEMBL5111561

SCHEMBL5111561

COc1ccccc1C(=O)Nc1c[nH]nc1-c1nc2c([nH]1)CCNC2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.43
MAPT P10636 3/20 0.43
NPC1 O15118 3/20 0.43
ALDH1A1 P00352 2/20 0.43
HPGD P15428 2/20 0.43
ADORA3 P0DMS8 1/20 0.43
ADORA2A P29274 1/20 0.43
ADORA1 P30542 1/20 0.43
KDM4E B2RXH2 1/20 0.43
TSHR P16473 2/20 0.42
GAA P10253 2/20 0.42
RXFP1 Q9HBX9 2/20 0.42
MAPK1 P28482 1/20 0.42
HSD17B10 Q99714 1/20 0.42
HSP90AA1 P07900 1/20 0.42
PKM P14618 1/20 0.42
PAX8 Q06710 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
TP53 P04637 1/20 0.42
MEN1 O00255 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5111445 0.85 CCNA2 (0.45) RAB9AMAPTALDH1A1KDM4EGAA
SCHEMBL5111914 0.83 BRPF1 (0.44) RAB9AMAPTNPC1ALDH1A1HPGD
SCHEMBL5111809 0.80 MAPK1 (0.42) RAB9AMAPTNPC1ALDH1A1HPGD
SCHEMBL5105503 0.80 MEN1 (0.38) RAB9AMAPTNPC1ALDH1A1HPGD
SCHEMBL5110963 0.80 CDK5 (0.39) HPGDMEN1KMT2APOLB
SCHEMBL5098938 0.79 ATR (0.40) RAB9AMAPTNPC1ALDH1A1HPGD
SCHEMBL5104896 0.79 MAPT (0.38) RAB9AMAPTNPC1ALDH1A1HPGD
SCHEMBL8302251 0.78 FOXO1 (0.64) RAB9AMAPTNPC1ADORA3ADORA2A
SCHEMBL5105859 0.76 CCNA2 (0.38)
SCHEMBL8305625 0.73 GAA (0.40) MAPTALDH1A1TSHRGAAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080004270-A1 3,4-Disubstituted Pyrazoles as Cyclin Dependent Kinases (Cdk) or Aurora Kinase or Glycogen Synthase 3 (Gsk-3) Inhibitors ASTEX THERAPEUTICS LIMITED (UK) 2008-01-03 US disclosed
EP-1781653-A1 3,4-DISUBSTITUTED PYRAZOLES AS CYCLIN DEPENDENT KINASES (CDK) OR AURORA KINASE OR GLYCOGEN SYNTHASE 3 (GSK-3) INHIBITORS Astex Therapeutics Limited (GB) 2007-05-09 EP disclosed
WO-2006003440-A1 3,4-DISUBSTITUTED PYRAZOLES AS CYCLIN DEPENDENT KINASES (CDK) OR AURORA KINASE OR GLYCOGEN SYNTHASE 3 (GSK-3) INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2006-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004270-A1 3,4-Disubstituted Pyrazoles as Cyclin Dependent Kinases (Cdk) or Aurora Kinase or Glycogen Synthase 3 (Gsk-3) Inhibitors CDK3, CDK1, GSK3B RAB9A 3974/4885MAPT 1805/4885NPC1 3115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.